About Onyx Pharmaceuticals (NASDAQ:ONXX)
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Onyx Pharmaceuticals (NASDAQ:ONXX) Frequently Asked Questions
What is Onyx Pharmaceuticals' stock symbol?
Onyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ONXX."
Who are some of Onyx Pharmaceuticals' key competitors?
Some companies that are related to Onyx Pharmaceuticals include CSL (CSL), Grifols SA, Barcelona (GRFS), Jazz Pharmaceuticals (JAZZ), ProMetic Life Sciences (PLI), Sirtex Medical (SRX), Mirati Therapeutics (MRTX), Organigram (OGI), Theratechnologies (TH), SIGA Technologies (SIGA), Sevion Therapeutics (SVON), VBI Vaccines (VBIV), XOMA (XOMA), Osiris Therapeutics (OSIR), Anavex Life Sciences (AVXL), Trillium Therapeutics (TRIL), ContraFect (CFRX), Medgenics (GNMX) and Concordia International (CXR).
How do I buy Onyx Pharmaceuticals stock?
Shares of Onyx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Onyx Pharmaceuticals?
Onyx Pharmaceuticals' mailing address is 249 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4804, United States. The biopharmaceutical company can be reached via phone at +1-650-2660000.
MarketBeat Community Rating for Onyx Pharmaceuticals (ONXX)
MarketBeat's community ratings are surveys of what our community members think about Onyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
|Community Ranking: || ||2.9 out of 5 ( )|
|Outperform Votes: || ||261 (Thanks for Voting!)|
|Underperform Votes: || ||185 (Thanks for Voting!)|
|Total Votes: || ||446|
Onyx Pharmaceuticals (NASDAQ:ONXX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Onyx Pharmaceuticals (NASDAQ:ONXX) Earnings History and Estimates Chart
Onyx Pharmaceuticals (NASDAQ ONXX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2013||Q2 2013||($0.42)||($0.40)||$151.73 million||$153.00 million||View||N/A|
|5/7/2013||Q1 2013||($0.47)||($0.19)||$134.36 million||$145.50 million||View||N/A|
|2/21/2013||Q4 2012||($0.76)||($0.36)||$113.17 million||$127.90 million||View||N/A|
|11/1/2012||Q312||($0.95)||($0.79)||$80.02 million||$89.51 million||View||N/A|
Onyx Pharmaceuticals (NASDAQ:ONXX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Onyx Pharmaceuticals (NASDAQ:ONXX)
No dividend announcements for this company have been tracked by MarketBeat.com
Onyx Pharmaceuticals (NASDAQ ONXX) Insider Trading and Institutional Ownership History
Onyx Pharmaceuticals (NASDAQ ONXX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/12/2013||Helen Torley||EVP||Sell||9,311||$126.89||$1,181,472.79||46,585|| |
|8/8/2013||Matthew Fust||CFO||Sell||2,492||$128.21||$319,499.32||40,303|| |
|8/7/2013||Suzanne Shema||EVP||Sell||4,052||$131.86||$534,296.72||34,618|| |
|8/6/2013||Kaye Foster-Cheek||SVP||Sell||8,878||$132.81||$1,179,087.18||27,066|| |
|7/30/2013||Corinne H Nevinny||Director||Sell||1,500||$131.26||$196,890.00|| |
|7/26/2013||Lopez Antonio J Grillo||Director||Sell||2,000||$130.50||$261,000.00|| |
|7/26/2013||Matthew K Fust||CFO||Sell||6,043||$130.50||$788,611.50|| |
|7/8/2013||Suzanne M Shema||EVP||Sell||4,052||$135.76||$550,099.52|| |
|7/2/2013||Matthew K Fust||CFO||Sell||1,551||$132.80||$205,972.80|| |
|7/1/2013||Juergen Lasowski||EVP||Sell||25,375||$132.63||$3,365,486.25|| |
|7/1/2013||Julianna R Wood||VP||Sell||2,304||$132.63||$305,579.52|| |
|7/1/2013||Paul Goddard||Director||Sell||6,000||$132.21||$793,260.00|| |
|6/19/2013||Corinne H Nevinny||Director||Sell||1,000||$88.25||$88,250.00|| |
|6/10/2013||Julianna R Wood||VP||Sell||2,306||$92.30||$212,843.80|| |
|6/7/2013||Suzanne M Shema||EVP||Sell||4,052||$91.23||$369,663.96|| |
|6/5/2013||N Anthony Coles||CEO||Sell||6,562||$90.00||$590,580.00|| |
|5/14/2013||Juergen Lasowski||EVP||Sell||4,182||$96.60||$403,981.20|| |
|5/13/2013||Helen Torley||EVP||Sell||8,250||$98.13||$809,572.50|| |
|5/13/2013||Matthew K Fust||CFO||Sell||10,269||$98.22||$1,008,621.18|| |
|4/11/2013||Lopez Antonio J Grillo||Director||Sell||43,164||$96.73||$4,175,253.72|| |
|4/10/2013||Julianna R Wood||VP||Sell||9,948||$95.00||$945,060.00|| |
|4/10/2013||Paul Goddard||Director||Sell||2,000||$95.00||$190,000.00|| |
|3/11/2013||Julianna R Wood||VP||Sell||3,331||$85.65||$285,300.15|| |
|3/11/2013||Magnus Lundberg||Director||Sell||5,000||$88.00||$440,000.00|| |
|10/5/2012||Juergen Lasowski||EVP||Sell||5,902||$90.00||$531,180.00|| |
|10/4/2012||Helen Torley||EVP||Sell||2,314||$86.51||$200,184.14|| |
|10/2/2012||Kaye I Foster-Cheek||SVP||Sell||2,015||$85.08||$171,436.20|| |
Onyx Pharmaceuticals (NASDAQ ONXX) News Headlines
Onyx Pharmaceuticals (NASDAQ:ONXX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Onyx Pharmaceuticals (NASDAQ:ONXX) Income Statement, Balance Sheet and Cash Flow Statement
Onyx Pharmaceuticals (NASDAQ ONXX) Stock Chart for Thursday, January, 18, 2018